Dermata Therapeutics, Inc. (DRMA) Operating income 2020–2025
Dermata Therapeutics, Inc. (DRMA) annual operating income history from SEC filings — each fiscal year as reported.
-$7.8MFY2025 · since FY2020: -$3.2M → -$7.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.8M | +37.9% |
| FY2024 | -$12.5M | -55.6% |
| FY2023 | -$8.0M | +16.9% |
| FY2022 | -$9.7M | -23.1% |
| FY2021 | -$7.9M | -147.6% |
| FY2020 | -$3.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More DRMA financial trends
DRMA RevenueDRMA Net incomeDRMA Net marginDRMA Gross profitDRMA Gross marginDRMA Operating marginDRMA Operating cash flowDRMA Free cash flowDRMA Capital expendituresDRMA Return on equityDRMA Stock buybacksDRMA Dividends paidDRMA Total assetsDRMA Total liabilitiesDRMA Shareholders’ equityDRMA overview →